Experimental Leukemia Drug Shows High Response Rates

Article

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

A novel treatment for a hard-to-treat form of leukemia showed high response rates during a recent phase 2 trial.

Treatment with venetoclax showed a clinically meaningful overall response rate of 79.4% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion.

Furthermore, 7.5% of patients achieved a complete response with or without complete recovery in the bone marrow.

The investigational small molecule selectively binds and inhibits to the BCL-2 protein that is vital in apoptosis. Researchers believe that blocking BCL-2 may restore the signaling system that instructs cancer cells to self-destruct.

The protein has also been linked to resistance in some blood cancers, and is expressed in CLL and non-Hodgkin’s lymphoma. The main study cohort enrolled 107 patients with relapsed or refractory disease, all of whom but one had 17p deletion.

Of the patients treated with venetoclax, 18 (17% of total patients, 21% of responders) showed no detectable cancer (MRD-negative) in a specific test. Of these 18 patients, 6 showed no detectable cancer in a bone marrow assessment.

At one year, 84.7% of all responses and 94.4% of MRD-negative responses maintained, with a progression-free survival rate of 72% and an overall survival rate of 86.7%.

The most common grade 3-4 adverse events were low white blood cell count (40%), low red blood cell count (18%), and low platelet count (15%).

“The high response rates, including complete responses and duration of response, demonstrate the potential of venetoclax to help people with this hard-to-treat type of leukemia,” said Sandra Horning, MD, Genentech chief medical officer and head of Global Product Development. “This is a patient population that has very few treatment options, and we are working with AbbVie to bring this new option to people as quickly as possible.”

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Mayo Clinic oncology pharmacy
Therapy session -- Image credit: pressmaster | stock.adobe.com
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Multiple myeloma awareness -- Image credit: Fauzi | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.